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Over the past several decades the experimental laboratory
has provided important insights into the pathophysiology of
acute myocardial infarction. Primarily on the basis of studies
in the dog (1), necrosis is believed to begin 20 to 30 min after
coronary artery occlusion and to progress over time like a
wave front, from endocardium to epicardium. Studies have
demonstrated that the amount of myocardium that becomes
necrotic after coronary occlusion is not predetermined but
can be reduced by timely application of appropriate thera-
pies, most notably myocardial reperfusion. Results from
animal experiments form the conceptual framework for the
current widespread use of thrombolytic and mechanical
reperfusion in patients with acute myocardial infarction.
Even in the absence of treatment, the amount of infarct
developing after complete coronary artery occlusion is ex-
tremely variable, ranging from none to perhaps 50% of the
left ventricle (2). This variability of infarct size arises di-
rectly from a concordant variability in the amount of myo-
cardium made ischemic, that is, the amount of myocardium
placed at risk. To determine whether a given treatment
modifies infarct size, it is necessary to measure the size of
the zone of myocardial risk in each experiment. The usual
method involves measuring both of the principal determi-
nants of myocardium at risk: the size of the occluded
coronary bed and the level of collateral blood flow (2,3). A
beneficial treatment reduces the size of the infarct as a
proportion of the zone at risk.
The present study. The study of Santoro et al. (4) in this
issue of the Journal is representative of one of several
attempts over the past 5 to 10 years to extrapolate the
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concepts and techniques of the experimental laboratory to
the clinical setting (5,6). The authors (4) used tomographic
perfusion imaging with technetium-99m isonitrile to measure
the amount of myocardium at risk before thrombolytic
therapy in patients with acute myocardial infarction. The
technetium-99m isonitrile was injected before administration
of the thrombolytic agent, and imaging was performed 3 to
4 h later in the nuclear medicine department. Because of
minimal myocardial redistribution of this radiopharmaceuti-
cal, the imaging study reflected the distribution of myocar-
dial blood flow before thrombolysis and, hence, indicated
the extent of myocardium at risk. When technetium-99m
isonitrile tomography was repeated at 5 days, the extent of
the perfusion defect at this later time was used as a measure
of the amount of necrosis that had developed. Areduction in
the size of the perfusion defect between the initial and 5 day
studies was considered to represent myocardial salvage. In
support of this conclusion, all seven patients with a large
decrease in the perfusion defect at 5 days had a patent
infarct-related vessel and improvement in wall motion by
echocardiography at 1 month. In contrast, four of the six
patients with a negligible reduction in defect size had an
occluded infarct-related vessel at 1 month, and none had
improvement in wall motion.
Despite the small number of patients, the study by
Santoro et al. (4) represents the first published report in
which technetium-99m isonitrile tomography was used to
assess the extent of myocardial salvage by thrombolytic
therapy in patients with acute myocardial infarction. Prelim-
inary results from several other groups (7-10) support the
feasibility of using technetium-99m isonitrile tomography for
this purpose, and the laboratory study by Verani et al. (11)
has provided experimental validation of this methodology.
Advantages and limitations of technetium·99m isonitrile
tomography. The property of minimal redistribution exhib-
ited by technetium-99m hexakis 2-methoxyisobutyl isonitrile
(Cardiolite) makes it ideal for measuring zone of myocar-
dium at risk in patients with acute infarction (12). Imaging
does not have to be completed before initiation of thrombol-
ysis, because the distribution of radionuclide remains essen-
tially constant for several hours. A delay in imaging may
actually be advantageous by permitting better patient stabil-
ity before transport to the imaging laboratory. Thallium-201,
the standard perfusion imaging agent, has not been used to
measure risk region because of concern that redistribution
might occur after thrombolysis. However, laboratory and
clinical studies (13,14) have shown that myocardial thallium-
201 redistribution is quite slow after injection at rest and that
redistribution is affected only minimally by reperfusion.
A practical limitation of technetium-99m isonitrile scin-
tigraphy in the setting ofacute infarction is the need to have
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the radiopharmaceutical prepared and available before the
start of thrombolytic therapy. Preparation generally takes 30
min and must be performed by a trained nuclear medicine
technologist. Thus, efficient lines of communication must be
established between the ambulance coordination center, the
emergency room and the nuclear medicine department, and
a technologist must be available on a 24 h basis.
Unless the patient has undergone spontaneous reperfu-
sion, the initial technetium-99m isonitrile perfusion defect
represents a direct visualization of the area at risk. To
outline the defect for quantification, edges must be drawn
around the left ventricle in each tomographic slice by extrap-
olating lines from the perfused parts of the ventricle with
visible technetium-99m isonitrile uptake. This procedure
often involves considerable guesswork. Another approach,
more cumbersome but potentially more accurate, involves
using the technetium-99m isonitrile tomogram to define the
amount of perfused left ventricle. The nonperfused area is
then determined by subtracting this amount from the total
left ventricular mass, obtained by another method such as
echocardiography or nuclear magnetic resonance (NMR)
imaging.
The follow-up perfusion defect, although certainly having
some relation to infarct size, does not directly demonstrate
necrotic myocardium. Depending on the importance of such
factors as the no reflow phenomenon, postreperfusion mi-
crovascular injury, patency of the infarct artery and the rate
of collateral vessel growth and enlargement, the extent of
poorly perfused myocardium several days after infarction
may not match the extent of myocardial necrosis. In general,
only the most necrotic central core of the infarct will remain
poorly perfused by this time (3,15). Even greater disparity
between flow and necrosis appears to exist when the follow-
up study is performed within 24 h of the infarction (8).
Consequently, it may prove more desirable to measure
infarct size by directly visualizing the infarcted myocardium.
Technetium-99m pyrophosphate tomography has been
shown to provide very good estimates of infarct size in
experimental animals (16). Indium-lll-labeled antimyosin
antibody (Myoscint) may prove even more useful because of
its closer correlation between tissue uptake and severity of
necrosis (17). Other potentially useful approaches include
positron emission tomographic measurement of the area of
myocardium devoid of 18P-2-deoxyglucose uptake (and
therefore presumably dead) (18) and nonradioactive meth-
ods, including NMR imaging (19) or spatially localized NMR
spectroscopy.
Conclusions. Prom a clinical point of view, it is important
to know the proportion of the risk region that becomes
infarcted in each patient with acute myocardial infarction.
This information is useful in assessing the risk of further
necrosis in the same vascular distribution and the need for
angioplasty or surgical revascularization. Technetium-99m
isonitrile imaging should theoretically be able to help in
making this assessment, but the practical problems alluded
to will probably prevent it from being used routinely in
patients with acute infarction. Patient transport out of the
coronary care unit could be avoided by using bedside planar
imaging instead of tomography, but the results would be
much less quantitative and therefore much less useful.
The most likely application of technetium-99m isonitrile
tomography in patients with acute infarction is in the re-
search setting. Because of our inability to make accurate
measurements of risk and infarct size in patients, we have
been forced to extrapolate results wholesale from the animal
laboratory to the clinic. However, with the availability of
new techniques such as technetium-99m isonitrile tomogra-
phy, we may now be in a position to examine the correctness
of some of our concepts about myocardial infarction in
patients. We would then be able to address important issues,
such as the time window available for meaningful myocardial
salvage with reperfusion, the amount of salvage achievable
by reperfusion and how myocardial salvage translates into
improved left ventricular function. We may also be able to
determine whether necrosis during reperfusion ("reperfu-
sion injury") represents a significant problem in patients and
whether adjunctive therapy given at the time of reperfusion
(Le., free radical scavengers) can improve myocardial sal-
vage over that seen with reperfusion alone.
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